Sentiment-Signal
21,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 15.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Direct |
| 02.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
Stammdaten
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Aura Biosciences, Inc. |
|---|---|
| Ticker | AURA |
| CIK | 0001501796 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 445,8 Mio. USD |
| Beta | 0,35 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -106,191,000 | -1.76 | 169,430,000 | 136,913,000 | |
| 2025-09-30 | 10-Q | -26,130,000 | -0.40 | 190,024,000 | 156,667,000 | |
| 2025-06-30 | 10-Q | -27,019,000 | -0.47 | 204,397,000 | 174,629,000 | |
| 2025-03-31 | 10-Q | -27,483,000 | -0.55 | 155,401,000 | 127,966,000 | |
| 2024-12-31 | 10-K | -86,919,000 | -1.75 | 182,503,000 | 151,970,000 | |
| 2024-09-30 | 10-Q | -21,042,000 | -0.42 | 205,340,000 | 174,668,000 | |
| 2024-06-30 | 10-Q | -20,337,000 | -0.41 | 218,282,000 | 191,454,000 | |
| 2024-03-31 | 10-Q | -19,706,000 | -0.40 | 235,025,000 | 208,783,000 | |
| 2023-12-31 | 10-K | -76,408,000 | -1.93 | 255,075,000 | 225,848,000 | |
| 2023-09-30 | 10-Q | -18,512,000 | -0.48 | 179,766,000 | 151,718,000 | |
| 2023-06-30 | 10-Q | -18,299,000 | -0.48 | 192,739,000 | 166,437,000 | |
| 2023-03-31 | 10-Q | -17,466,000 | -0.46 | 206,019,000 | 180,258,000 | |
| 2022-12-31 | 10-K | -58,763,000 | -1.96 | 223,935,000 | 195,583,000 | |
| 2022-09-30 | 10-Q | -15,901,000 | -0.54 | 143,147,000 | 115,054,000 | |
| 2022-06-30 | 10-Q | -13,468,000 | -0.46 | 135,021,000 | 129,091,000 | |
| 2022-03-31 | 10-Q | -12,835,000 | -0.44 | 146,422,000 | 141,086,000 | |
| 2021-12-31 | 10-K | -35,251,000 | -8.95 | 160,030,000 | 152,315,000 | |
| 2021-09-30 | 10-Q | -8,838,000 | -28.33 | 90,704,000 | -131,015,000 | |
| 2021-06-30 | 10-Q | -8,852,000 | -28.53 | -122,751,000 | ||
| 2021-03-31 | 10-Q | -5,927,000 | -114,190,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Kilroy Conor | Officer, See Remarks | Open Market Sale | -11,738 | 7.02 | -82,400.76 | -109,5% | |
| 2026-02-17 | Plavsic Mark | Officer, Chief Technology Officer | Open Market Sale | -15,890 | 5.05 | -80,244.50 | -106,7% | |
| 2026-02-17 | Kilroy Conor | Officer, See Remarks | Open Market Sale | -12,079 | 5.05 | -60,998.95 | -81,1% | |
| 2025-10-16 | Plavsic Mark | Officer, Chief Technology Officer | Open Market Sale | -12,169 | 6.35 | -77,273.15 | -102,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.